Apotex Can't Launch Generic Pulmicort Yet: Judge

Law360, New York (April 16, 2009, 12:00 AM EDT) -- A federal court has temporarily blocked Apotex Inc. from launching a generic version of Pulmicort Respules, AstraZeneca Pharmaceuticals LP’s successful asthma treatment for children.

AstraZeneca said Thursday the U.S. District Court for the District of New Jersey had granted its motion for a temporary restraining order against the Canadian generic-drug maker and set a hearing for April 27 to consider whether the ban should be continued.

“AstraZeneca has full confidence in the strength of its intellectual property rights protecting Pulmicort Respules and will continue to vigorously...
To view the full article, register now.